Prostate cancer biomarkers tests
Innovative non-invasive prostate cancer biomarker testing helps to identify prostate cancer risk and aggressiveness more accurately and, in some cases, to avoid additional complex and painful testing.
Prostate cancer today is the most common malignant disease in men in Lithuania; therefore special attention is paid to its early diagnosis. Men at risk are first screened with a prostate-specific antigen (PSA) test and, if elevated values are reported, a prostate biopsy examination is then carried out.
Experience shows that due to the high sensitivity of PSA, nearly half of the biopsies are performed unnecessarily. Biopsies are invasive and uncomfortable.
A new, innovative non-invasive study of prostate cancer biomarkers – a liquid biopsy-based molecular test performed on a patient's urine sample – allows the cancer risk and probability to be assessed more accurately thus avoiding complex and painful examinations, including unnecessary biopsies in some cases. This test is particularly relevant for patients with mild elevations in PSA for whom the need for additional invasive testing is being considered. The test helps to assess the risk of prostate cancer and to make a decision regarding a prostate biopsy.
The prostate cancer biomarker test is painless and non-invasive; no preparation is required.
The test is done using a urine sample.
These non-invasive urine tests are is usually performed only after the prostate examination carried out by a physician urologist – digital rectal palpation of a prostate. Pre-registration is required for a consultation with a urologist.
Cost of prostate cancer biomarker test
Regular price Regular For clients who are not covered by compulsory health insurance
A non-invasive urine test SelectMDx for prostate cancer (the mRNA levels of the DLX1 and HOXC6 biomarkers)**
A non-invasive urine test for prostate cancer with PCA3, TMPRSS2:ERG biomarkers (result during 7 w. d.)
A non-invasive urine test for prostate cancer with PCA3, TMPRSS2:ERG biomarkers (result during 72 h)
What factors affect the price?
The prices indicated below apply to citizens of the Republic of Lithuania and the European Union.
If you are coming from another country please check the price by telephoning or sending an email.
When are the examinations are carried out:
2 hours for the most common (routine) blood tests and urinalysis.
The reports of computed tomography (CT), magnetic resonance tomography (MRT) imaging and other
instrumental examinations are usually ready immediately, i.e within 2-3 hours after the examination.
Why it is worth
To be examined at our Centre?
- Painless, non-invasive, safe and rapid test.
- We perform high quality tests which has been confirmed by the ISO 15189 certification of our laboratory.
- The results of the tests performed in our laboratory are explained by our staff, a service that is provided by only a few laboratories in the country.
- There is no risk of damaging or confusing test samples during transportation which is statistically one of the most common causes of blood sample damage in the laboratories.
Good to know
The test is designed for those with a suspected diagnosis of prostate cancer for whom a prostate biopsy is being considered. The test reveals the probability of aggressive prostate cancer and shows whether a prostate biopsy is really appropriate.
This non-invasive urine test is carried out just after a prostate examination - a digital rectal prostate palpation, which is performed by an urologist. The doctor palpates the prostate gland and checks whether it is hard, and whether there are nodules, surface bumps or unevenness.
A patient's urine sample is then taken and a reverse transcription polymerase chain reaction assay is made to measure the levels of certain biomarkers in the urine.
- Much more sensitive, accurate, and specific than the widely used PSA urine test.
- Prostate cancer biomarkers PCA3 and TMPRSS2: ERG have been identified and are considered by many researchers to be among the most reliable.
- The result indicates the risk of clinically significant cancer and the likelihood that a biopsy would be positive.
- If a low risk of clinically significant cancer is identified, a biopsy may be omitted. This would allow avoiding up to 45% of unnecessary biopsies and related complications.
Prostate biopsy has been linked to pain, anxiety and complications.
A prostate biopsy is an invasive test that confirms a diagnosis of cancer if you suspect an increase in serum PSA. The biopsy is performed with special needles, taking pieces of prostate tissue and examining them in the laboratory. Because the biopsy removes very small amounts of prostate tissue (less than 1% of the prostate volume), the cancer may not be diagnosed simply because it has been 'missed'.
An invasive prostate biopsy procedure can lead to complications such as infections, sepsis, haematuria.
Blood serum PSA levels may be elevated for a variety of non-cancerous reasons, such as inflammation, physical activity etc. For these reasons, about half of the biopsies performed are negative: as many as 65-75 % of first-time biopsies and 10-35 % of repeated biopsies are negative.
An accurate prognosis after a non-invasive prostate cancer biomarker test can protect you from a potentially unnecessary prostate biopsy!
- Prostate cancer aggressiveness is usually measured by the Gleason system – a higher score indicates a more aggressive disease, and the higher likelihood of metastasis.
- If the Gleason score is 6 or less, the tumour cells are well differentiated, non-malignant.
- If the Gleason score is 7 or higher, the cancer is poorly differentiated, aggressive, and the risk of metastasis increases.
- In the presence of a high risk of clinically significant prostate cancer, a prostate tissue sample, a biopsy, is required to confirm the final diagnosis.
- The results of the tests will be ready within 4-7 business days.
You can pick them up at a reception or we can send them to you by e-mail if you wish.
- For laboratory interpretation, contact the laboratory at tel. (8 5) 247 64 22.